Dr. Dingwei Ye 叶定伟
Oncology
Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public sources. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions
- Vice President
- Head of Urologic Oncology, Fudan University Shanghai Cancer Center
Checked against a public report (2026-06). Positions change; the hospital's website is the final word.
Clinical focus: Radical prostatectomy and robotic surgery; radical cystectomy with urinary diversion; nephron-sparing surgery for kidney cancer; systemic therapy for advanced urologic tumors; prostate biopsy and early screening.
Conditions and procedures: Prostate cancer, Bladder cancer, Kidney cancer, Advanced urologic tumors
Compiled from public information; not confirmed with the hospital or the doctor.
Name order: in Chinese the family name comes first (Ye Dingwei). Papers usually list the name as Dingwei Ye.
Selected publications
73 first- or senior-author papers on PubMed where the author's own affiliation is this hospital (73 since 2016), counted among the 200 most recent matching papers. Most recent:
- Cancer Med, 2026 (senior author): Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3-Rearranged Renal Cell Carcinoma: A Multicenter Real-World Study. PubMed 42726730
- Oncogene, 2026 (senior author): METTL5-mediated rRNA modification controls prostate cancer progression through the IRF7/DNA2 axis and mitophagy regulation. PubMed 42437825
- Asian J Androl, 2026 (senior author): Real-world effectiveness and safety of radium-223 therapy in castration-resistant prostate cancer with bone metastases. PubMed 41774055
- J Robot Surg, 2026 (senior author): Early matched comparison of a novel modular carina robotic platform and the da vinci system for robot-assisted radical prostatectomy. PubMed 42474819
- Cell Death Differ, 2026 (senior author): TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways. PubMed 42288623
- Curr Gene Ther, 2026 (senior author): APOL3 Orchestrates Metastasis and Enzalutamide Resistance via STAT3-DAB2IP Signaling in Prostate Cancer. PubMed 42220127
- Signal Transduct Target Ther, 2026 (senior author): Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial. PubMed 41968137
- Int J Urol, 2026 (first author): Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study. PubMed 42015879
Each paper was checked automatically: the author listed with this name must give this hospital as their affiliation. See the full PubMed search.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and recommend a treatment plan.
Get a specialist opinion